SK Bioscience Co Ltd stock (KR7326030004): National Growth Fund backing and valuation metrics in focus

SK Bioscience Co Ltd shares are in focus after reports that South Korea's National Growth Fund will provide a 300 billion won facility to support late-stage vaccine development, while investors reassess the stock's valuation on the KRX.

SK Bioscience Co Ltd shares listed on the Korea Exchange are drawing attention on 05/29/2026 after reports that South Korea's National Growth Fund has approved financing of 300 billion won to support the company's vaccine pipeline, including late-stage trials of its 21-valent pneumococcal candidate GBP410, sharpening the focus on valuation for the South Korea-based vaccine developer.

According to Korean media cited by financial portal ad-hoc-news.de on 05/29/2026, the National Growth Fund facility is intended to accelerate Phase 3 development of GBP410 and strengthen SK Bioscience's broader research and development platform, highlighting the role of domestic policy support in the country's biopharmaceutical sector and its KRX-listed constituents.

The stock traded on the Korea Exchange under ticker 302440 in South Korean won on 05/29/2026, keeping SK Bioscience within the universe of healthcare names followed by local investors, while the National Growth Fund decision underscores the government's intent to back vaccine innovation as part of South Korea's broader industrial strategy.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: SK Bioscience
• Sector/industry: Biopharmaceuticals and vaccines
• Headquarters/country: Seongnam, South Korea
• Core markets: South Korea, emerging markets in Asia and Latin America
• Key revenue drivers: Human vaccines, contract manufacturing and R&D partnerships
• Home exchange/listing venue: Korea Exchange (302440)
• Trading currency: KRW

SK Bioscience Co Ltd: core business model

SK Bioscience concentrates on developing, manufacturing and supplying vaccines while leveraging contract development and manufacturing services for global partners to monetize its production capacity and research capabilities.

Valuation metrics and multiples for SK Bioscience Co Ltd

As a KRX-listed healthcare issuer, SK Bioscience is typically assessed against South Korean biopharmaceutical peers using earnings-based and cash-flow-based valuation metrics, with key ratios including price-earnings multiples and enterprise value to EBITDA benchmarks that investors follow to gauge how the market prices its vaccine pipeline and manufacturing assets relative to domestic and regional competitors.

The recent news that the National Growth Fund has committed 300 billion won of financing for GBP410 Phase 3 development and related research spending introduces an additional dimension to fundamental analysis, as market participants weigh how non-dilutive funding support and potential future product launches might flow through to revenue, operating margins and, ultimately, valuation multiples for the Seongnam-headquartered company.

Conclusion

The reported 300 billion won National Growth Fund facility gives SK Bioscience Co Ltd additional resources to advance GBP410 and related vaccine programs, reinforcing its strategic position within South Korea's state-supported biopharmaceutical ecosystem.

On a valuation-focused Friday, investors are likely to integrate the potential impact of this financing on future earnings power and balance-sheet strength into their assessment of earnings multiples and cash-flow-based measures for the Korea Exchange-listed stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.